Rulla M Tamimi

Jul 31, 2024 | nature.com | Yue Zheng |Kathryn J. Ruddy |Rulla M Tamimi |Virginia F. Borges

AbstractOvarian function suppression (OFS) benefits young women with hormone receptor (HR)-positive breast cancer but they are at risk for ovarian function breakthrough. We assessed endocrine effects of gonadotropin-releasing hormone agonist (GnRHa) treatment in a prospective cohort of patients aged ≤ 40 years with HR-positive breast cancer. Plasma estradiol (E2), estrone, and follicule-stimulating hormone (FSH) levels were measured from blood samples drawn 1 and 4 years after diagnosis.

Apr 25, 2023 | nature.com | Yue Zheng |Kathryn J. Ruddy |Rulla M Tamimi |Virginia F. Borges |Lisa Carey |Eric P. Winer

AbstractExtended adjuvant endocrine therapy (eET) improves outcomes in breast cancer survivors. Most studies however have been limited to postmenopausal women, and optimal eET for young survivors is uncertain. We report eET use among participants in the Young Women’s Breast Cancer Study (YWS), a multicenter prospective cohort of women age ≤40 newly diagnosed with breast cancer enrolled between 2006–2016.